The Mid and South Essex Integrated Commissioning Board has advised us of the following eligibility criteria for Tirzepatide (Mounjaro):

Tirzepatide (Mounjaro) will not be accessible to anyone who wishes to use it. 

People with the highest health risks and who meet the clinical criteria will be prioritised.  Full qualifying clinical criteria is a BMI (Body Mass Index) of 40 or more plus four or more of the following diagnosed health conditions:

• type 2 diabetes
• high blood pressure
• heart disease
• obstructive sleep apnoea
• abnormal blood fats (dyslipidaemia)

Access to the drug must be accompanied by wraparound care which will include support for people to make dietary changes and to increase physical activity.  Tirzepatide will not be prescribed as a standalone treatment, and patients must fully participate with the wraparound support programme.

Tirzepatide (Mounjaro®) might not be considered clinically suitable for everyone and not everyone who meets the eligibility criteria will want to use it to support their weight loss. Therefore, there are a number of alternative weight management services available in mid and south Essex.